Troglitazone (Rezulin, Resulin, Romozin, Noscal) is an antidiabetic and anti-
inflammatory drug, and a member of the drug class of the thiazolidinediones.
During all clinical studies in North America, a total of 48 of 2510 (1.9%) Rezulin (
troglitazone removed from the us market 3/21/00) -treated patients and 3 of 475 ...
troglitazone | C24H27NO5S | CID 5591 - structure, chemical names, physical and
chemical properties, classification, patents, literature, biological activities, ...
Troglitazone, a peroxisome proliferator–activated receptor gamma agonist, which
enhances insulin sensitivity, was approved for the treatment of type 2 diabetes ...
FDA Endocrine and Metabolic Drugs Advisory Committee Meeting on
Troglitazone. The last time I appeared before this advisory committee to present ...
Sigma-Aldrich offers Sigma-T2573, Troglitazone for your research needs. Find
product specific information including CAS, MSDS, protocols and references.
Resulin™. Troglitazone is a TZD which was approved for the treatment of insulin
resistance and hyperglycemia in Type II diabetes, under the trade name ...
Aug 14, 2013 ... Rezulin (troglitazone). Parke-Davis/Warner Lambert agree to FDA's request to
withdraw Rezulin from the market. FDA asked ...
Petition to the Food and Drug Administration requesting that it immediately
require labeling for the diabetes drugs troglitazone (Rezulin), rosiglitazone (
EDITORIALS. Insight Into Hepatotoxicity: The Troglitazone. Experience. See
Article on Page 237. Troglitazone entered the U.S. market in 1997 as the first